Interim Safety Data in Ph 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients Reported July 22, 2026
Ph 3 Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as 1L PD-L1-Neg Non-Squamous NSCLC Met Primary Endpoint July 22, 2026
KEYTRUDA Monotherapy Significantly Improved PFS vs chemo in Certain Patients With Advanced or Recurrent MMR-deficient Endometrial Cancer July 22, 2026
AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies July 22, 2026
First Patient Dosed in Ph 1 Trial of IM-3050 in Patients with FAP-Expressing Advanced Solid Tumors July 22, 2026
